TALVEY
As listed in the register: TALVEY 2 MG/ML SOLUCION INYECTABLE
2 MG/ML · solución inyectable
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Talquetamab
- Made by
- Janssen-Cilag International N.V
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (TALVEY). It describes the substance, not this exact product.
Talquetamab-tgvs is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D) expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as healthy tissues such as epithelial cells in keratinized tissues of the skin and tongue.
In vitro, talquetamab-tgvs activated T-cells caused the release of proinflammatory cytokines and resulted in the lysis of multiple myeloma cells.
Talquetamab-tgvs is expected to be metabolized into small peptides by catabolic pathways.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-10-08
Safety of the active substance
From the US prescribing label for the same active substance (TALVEY). It describes the substance, not this exact product.
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TALVEY.
The most common Grade 3 or 4 laboratory abnormalities (≥30%) are lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, and hemoglobin decreased.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Janssen-Cilag International N.V |
|---|---|
| Active substance | Talquetamab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 2 MG/ML |
| Form | solución inyectable |
| Classification | L01FX29 · Cancer treatments and immune-system medicines |
| Route | vía subcutánea |
| Marketed | Yes, according to the register |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | TALVEY 2 MG/ML SOLUCION INYECTABLE |
| Nº Registro | 1231748001 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solución inyectable2 products
- 2 MG/ML
- 40 MG/ML
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.